Theravance Biopharma: Newtyn reports zero-share stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Theravance Biopharma, Inc. (TBPH) is the issuer in an exit ownership filing by Newtyn Management, LLC, investment manager for Newtyn TE Partners, LP and Newtyn Partners, LP. As of September 30, 2026, Newtyn Management reported zero ordinary shares beneficially owned; each partnership also held zero shares. The report lists zero sole and shared voting and dispositive power and zero percent ownership.
Key Figures
Key Terms
beneficially own regulatory
exit filing regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.